213 related articles for article (PubMed ID: 28183221)
1. Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
El Sayed A; Barbati ZR; Turner SS; Foster AL; Morey T; Dieterich DT; Fierer DS;
HIV Clin Trials; 2017 Mar; 18(2):60-66. PubMed ID: 28183221
[TBL] [Abstract][Full Text] [Related]
2. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
Del Bello D; Cha A; Sorbera M; Bichoupan K; Levine C; Doyle E; Harty A; Patel N; Ng M; Gardenier D; Odin J; Schiano TD; Fierer DS; Berkowitz L; Perumalswami PV; Dieterich DT; Branch AD
Clin Infect Dis; 2016 Jun; 62(12):1497-1504. PubMed ID: 26936665
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
Rockstroh JK; Bhagani S; Hyland RH; Yun C; Dvory-Sobol H; Zheng W; Brainard DM; Ingiliz P; Lutz T; Boesecke C; Nelson M
Lancet Gastroenterol Hepatol; 2017 May; 2(5):347-353. PubMed ID: 28397698
[TBL] [Abstract][Full Text] [Related]
5. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiviral therapy for HCV on lipid levels.
Mauss S; Berger F; Wehmeyer MH; Ingiliz P; Hueppe D; Lutz T; Simon KG; Schewe K; Rockstroh JK; Baumgarten A; Christensen S
Antivir Ther; 2017; 21(1):81-88. PubMed ID: 27685337
[TBL] [Abstract][Full Text] [Related]
7. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
[TBL] [Abstract][Full Text] [Related]
9. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Luetkemeyer AF; McDonald C; Ramgopal M; Noviello S; Bhore R; Ackerman P
Clin Infect Dis; 2016 Jun; 62(12):1489-96. PubMed ID: 27025835
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
Castells L; Llaneras J; Campos-Varela I; Bilbao I; Crespo M; Len O; Rodríguez-Frías F; Charco R; Salcedo T; Esteban JI; Esteban-Mur R
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):86-93. PubMed ID: 28051797
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy.
Johnson TM; Sison R; Fallon JP; Shukla PP; Bhattarai S; Galang H; Habeeb R; Slim J
HIV Clin Trials; 2016 Nov; 17(6):242-245. PubMed ID: 27846791
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China.
Chen L; Du L; Kang S; Ma F; Li C; He M; Bai L; Tang H
Sci Rep; 2021 May; 11(1):11301. PubMed ID: 34050222
[TBL] [Abstract][Full Text] [Related]
13. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis.
Li G; Zang K; Zhang G; Zhu D; Deng X
Virol J; 2018 Jan; 15(1):19. PubMed ID: 29351766
[TBL] [Abstract][Full Text] [Related]
15. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
16. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
Aliment Pharmacol Ther; 2015 Sep; 42(5):559-73. PubMed ID: 26113432
[TBL] [Abstract][Full Text] [Related]
18. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
[TBL] [Abstract][Full Text] [Related]
19. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
Dolatimehr F; Karimi-Sari H; Rezaee-Zavareh MS; Alavian SM; Behnava B; Gholami-Fesharaki M; Sharafi H
Daru; 2017 Apr; 25(1):11. PubMed ID: 28427463
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.
Fierer DS; Dieterich DT; Mullen MP; Branch AD; Uriel AJ; Carriero DC; van Seggelen WO; Hijdra RM; Cassagnol DG;
Clin Infect Dis; 2014 Mar; 58(6):873-9. PubMed ID: 24336914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
